Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on November 1, 2021. The filing serves to announce the company's financial results for the third quarter ended September 30, 2021. Lantern Pharma is an emerging growth company incorporated in Delaware, with its common stock (LTRN) trading on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a notification that a press release (Exhibit 99.1) and a presentation (Exhibit 99.2) containing these details have been issued and are incorporated by reference, but the figures themselves are not listed within the body of this 8-K.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in this specific filing text. The document solely references the upcoming release of Q3 2021 results.
Guidance, Outlook, and Risks
Management indicated that a conference call and live webcast would be hosted on November 1, 2021, to discuss financial and operating results. The filing includes standard disclaimers stating that the information in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Presentation) for management's outlook, clinical trial updates, and guidance.
- Verify the company's cash runway and burn rate as disclosed in the referenced press release.
- Confirm any updates on the status of the company's drug development pipeline mentioned in the conference call materials.